Question No. 53 Ms. Kirsty Duncan: With respect to the chronic cerebrospinal venous insufficiency (CCSVI) clinical trial being undertaken by Dr. Traboulse: (a) what milestones are reportable to the government, (i) on what date(s) is reporting expected to occur, (ii) how will this information be communicated to patients, the medical community, and the general public; (b) on what date did each of the trial sites pass ethical review; (c) on what date did recruitment of patients begin for each of the trial sites; (d) how many patients with multiple sclerosis (MS) are being recruited for each site, and how is consistency in diagnosis and treatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) ho ...[+++]w is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with bo ...

In a context where we already have staff asking us to assist them with this training process, when we have Dr. Mullan urging a training process for correctional staff.Our concern is that if this kind of discretion is placed in the hands of individuals who aren't trained, it may result in increased tensions within the prison, instead of complaints being resolved and the grievance system’s being the safety valve it's intended to be.

General information on the "Executive Training Programme" (brochures, video presentation in the nine official languages) may be obtained from the Commission in Brussels by contacting: Mr. Rudie FILON Directorate General for External Relations Japan Division (B-28/6-127) 200, rue de la Loi B-1049 BRUXELLES Phone (32.2) 29.90.062 Fax (32.2) 29.90.203 - - - (2) see Annex 2 EUROPEAN COMMUNITY EXECUTIVE TRAINING PROGRAMME IN JAPAN (ETP 12) MAY 1992 - NOVEMBER 1993 PARTICIPANT COMPANY SECTOR Mr. G. Aberlenc Calberson International Freight Forwarding Mr. I. Allison James Gent Co. Ltd. Toiletries Mr. A. Avides Moreira ICEP Export Promotion Mr. S. Brevi OMB Spa For ...[+++]ged Steel Valves Mr. Ch. Bringuier Houles House Furnishings Mr. J. Broeders Van Ommeren Ceteco NV Transport Mr.A.Casablancas Vilanova Banco Santander Banking Mrs. S. Chevallier Compagnie Bancaire Banking Mr. A. Dimokas Olympic Airways Airline Mr. A. Dumerc Alcatel Espace Satellites Mr. E. Eller Deutsche Aerospace Aerospace Mr. W. Finckh Voith Turbo GmbH Co. KG Transmission Tool Machines Mr. S. Fonseca ICEX Export Promotion Mr. C. Fragides Del Monte SA Foodstuffs Mr. J. Frey KSB Aktiengesellschaft Pumps and Valves Mr. J. Fritzboeger Novo Nordisk A/S Pharmaceuticals Mr. R. Garreis Carl Zeiss Optics/Precision Engineering Mr. A. Garrofé Pujol Bufete Cuatracasas Law firm Mr. M. Genot A. F.